7 695

Cited 0 times in

Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome

DC Field Value Language
dc.contributor.author김흥동-
dc.contributor.author은호선-
dc.contributor.author이영목-
dc.contributor.author이준수-
dc.contributor.author강훈철-
dc.contributor.author권은지-
dc.contributor.author김신혜-
dc.date.accessioned2014-12-19T17:40:03Z-
dc.date.available2014-12-19T17:40:03Z-
dc.date.issued2012-
dc.identifier.issn1059-1311-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/91843-
dc.description.abstractPURPOSE: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). METHODS: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period. RESULTS: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency. CONCLUSIONS: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfSEIZURE-EUROPEAN JOURNAL OF EPILEPSY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdolescent-
dc.subject.MESHAnticonvulsants/administration & dosage*-
dc.subject.MESHChild-
dc.subject.MESHChild, Preschool-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHInfant-
dc.subject.MESHIntellectual Disability/drug therapy*-
dc.subject.MESHLennox Gastaut Syndrome-
dc.subject.MESHMale-
dc.subject.MESHSpasms, Infantile/drug therapy*-
dc.subject.MESHTriazoles/administration & dosage*-
dc.titleRufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pediatrics (소아과학)-
dc.contributor.googleauthorShin Hye Kim-
dc.contributor.googleauthorSo-Hee Eun-
dc.contributor.googleauthorHoon-Chul Kang-
dc.contributor.googleauthorEun Ji Kwon-
dc.contributor.googleauthorJung Hye Byeon-
dc.contributor.googleauthorYoung-Mock Lee-
dc.contributor.googleauthorJoon Soo Lee-
dc.contributor.googleauthorBaik-Lin Eun-
dc.contributor.googleauthorHeung Dong Kim-
dc.identifier.doi22421185-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01208-
dc.contributor.localIdA02635-
dc.contributor.localIdA02955-
dc.contributor.localIdA03177-
dc.contributor.localIdA00102-
dc.contributor.localIdA00242-
dc.contributor.localIdA00677-
dc.relation.journalcodeJ02648-
dc.identifier.eissn1532-2688-
dc.identifier.pmid22421185-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S1059131112000453-
dc.subject.keywordRufinamide-
dc.subject.keywordLennox-Gastaut syndrome-
dc.subject.keywordChild-
dc.contributor.alternativeNameKim, Heung Dong-
dc.contributor.alternativeNameEun, Ho Seon-
dc.contributor.alternativeNameLee, Young Mock-
dc.contributor.alternativeNameLee, Joon Soo-
dc.contributor.alternativeNameKang, Hoon Chul-
dc.contributor.alternativeNameKwon, Eun Ji-
dc.contributor.alternativeNameKim, Shin Hye-
dc.contributor.affiliatedAuthorKim, Heung Dong-
dc.contributor.affiliatedAuthorEun, Ho Seon-
dc.contributor.affiliatedAuthorLee, Young Mock-
dc.contributor.affiliatedAuthorLee, Joon Soo-
dc.contributor.affiliatedAuthorKang, Hoon Chul-
dc.contributor.affiliatedAuthorKwon, Eun Ji-
dc.contributor.affiliatedAuthorKim, Shin Hye-
dc.citation.volume21-
dc.citation.number4-
dc.citation.startPage288-
dc.citation.endPage291-
dc.identifier.bibliographicCitationSEIZURE-EUROPEAN JOURNAL OF EPILEPSY, Vol.21(4) : 288-291, 2012-
dc.identifier.rimsid29952-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.